with millions of people scrambling to but the new phone LOL!!! Im not saying its warranted but the legions of aapl fans will buy a bucket of bird s#$% if aaple sells it:) im laughing all the way to the bank!
I've was a shareholder of lumera on the management pump job that took their market cap to over 200 million, the gig takeover has been even more of a disaster for the lumera shareholder as the share count here has exploded and lumera is now a minority interest in a foreign development co, funny the lead development scientist Dr Dinu is now a slesman, #$%$, avi is the only winner here, not us that's for sure, I have much less shares than you but they likely cost me just as much as you
Futures increased as much as 0.9 percent in New York. The U.S. will join the European Union in stiffening sanctions on Russia over Ukraine, prompting the government in Moscow to threaten retaliation. U.S. retail sales probably rose in August after stagnating the previous month, according to a Bloomberg survey. Brent futures are down 2.2 percent in London this week.
The market is short shares to sale. The demand has out striped the supply. The IPO managers have talked about doing a secondary IPO if more shares are needed to meet the demand for retail investors.
They say that is why the price keeps rising for the stock. I found more info on why out of all those shares. It's still not enough. Alibaba lured large investors, nearly half the shares were placed with just 25 funds.
People with knowledge of the matter said. It helped that the shares were offered at a compelling discount to other Chinese Internet companies. A gap that has disappeared after the gains, the IPO discount was certainly erase
It may be $70 next spring but it will be $115 tomorrow. Shorts are too funny, the higher she goes the dumber their post !
Sentiment: Strong Buy
Multiple reasons. All know that Al has altruistic intensions to see Afrezza gets to those who need it. Al doesn't need more money. Don't get me wrong, of course he is all for earnings, I just don't think with regards to Afrezza, its his #1 priority. He wanted to be sure MNKD didn't partner with a BP who would bury Afrezza. This was not missed by SNY. And it gave them bargaining power, as did their Lantus product which is the perfect match for Afrezza. Lantus being a perfect match for Afrezza was not missed by Al. Al develops his products for the good of the sick first. The monetary earnings he knows will come, but to him are an afterthought. ( I know this is hard to believe to many here, putting the good of sick folks ahead of earnings). But Al has experience and knows that a great product will sell, and sell big. He's also smart enough to realize that it would not sell at all if someone like SNY didn't market it with its massive, worldwide sales force. This was also not missed by SNY. It gave SNY another bargaining chip in the partnering process. Ask yourself this, If not a partnership with SNY, then with whom?" What other BP could Al have been assured of getting Afrezza to those who need it worldwide? Who else has a rival to Lantus? Who else could be a viable partner that together with MNKD could be certain to monopolize the entire world's insulin/diabetes treatment? That's right, no one. And Al was smart enough to see it and to know that 35% of the world is gigantic, and much more than 50-75% of earnings that would have come from a deal with anyone other than SNY.
" I bet Judge Vaughn does throw the book at him."
Since Judge Vaughn isn't the judge for the Oct. 2nd motion, how exactly will he throw the book at Wallace? You're an idiot.
FRP: (looks like a strike is about to start there) 8.07
OTEL: 4.47 (a yahoo thing, actually 4.30)
This is what the Market is paying for current earnings in this space. Numbers from yahoo, which have a credibility problem. But still, usually close. The lower numbers are a lower multiple.
The contrast between Dr. West at BioTime with it's Asterias subsidiary rapidly receiving FDA approval for the cervical spinal cord injury vs. Geron's management being hamstrung by an illogical FDA holds is interesting. It suggests a contrast in political weight and industrial savvy.